The new WHO global strategic initiative encouraged countries to adopt digital health tools to support universal health coverage.

Black and Hispanic patients with MCC are more likely to have tumors on UV-protected sites, which is associated with better outcomes.

Concomitant IBD reduces disease control and treatment response among patients with PsA receiving biologic therapy.

Ixekizumab was more effective for the treatment of mild to moderate psoriasis vs severe psoriasis at most time points through 52 weeks.

Credit: Getty Images Clinical guidelines on the management of atopic eczema have been updated to reflect new and expanded medication approvals. An updated evidence- and consensus-based living ...

Beau’s lines are transverse grooves that form along the nails of the fingers or toes. 1 They can appear after a stressor, such as a medication, underlying health condition, trauma, or infection, ...

This is a comprehensive table of dermatology ICD-10 codes used by researchers and healthcare professionals and personnel – nurses, medical coders, physicians, et al. This table has been curated for ...

Patients with cutaneous squamous cell carcinoma and immunosuppression were more likely to experience local recurrence, nodal involvement, metastasis, and disease-specific mortality than patients ...

Livedo reticularis is a mottled discoloration of the skin. The discoloration may appear blotchy with a net-like pattern and range from reddish-blue to purple. 1,2 Although the terms used in the ...

Because they are rare and can look like several other conditions, knuckle pads might not be as easily recognized as other hyperkeratotic or fibrous lesions. Familiarity with the risk factors and ...

A multimodality approach to treating melasma may be the most successful. An international team of researchers summarizes the available medical therapies for melasma and offers suggestions and ...

Patients with inflammatory diseases — including psoriasis, rheumatoid arthritis, and inflammatory bowel disease — who received tumor necrosis factor inhibitors are at a greater risk for non-melanoma ...